These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 1856148)

  • 1. The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens.
    Marik PE; Havlik I; Monteagudo FS; Lipman J
    J Antimicrob Chemother; 1991 May; 27 Suppl C():81-9. PubMed ID: 1856148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum concentrations and safety of single daily dosing of amikacin in children undergoing bone marrow transplantation.
    Viscoli C; Dudley M; Ferrea G; Boni L; Castagnola E; Barretta MA; Lanino E; Loy A; Moroni C; Somenzi M
    J Antimicrob Chemother; 1991 May; 27 Suppl C():113-20. PubMed ID: 1856140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis.
    Abdel-Hady E; El Hamamsy M; Hedaya M; Awad H
    J Clin Pharm Ther; 2011 Feb; 36(1):45-52. PubMed ID: 21198719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Ann Intern Med; 1993 Oct; 119(7 Pt 1):584-93. PubMed ID: 8363169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients.
    Marik PE; Lipman J; Kobilski S; Scribante J
    J Antimicrob Chemother; 1991 Nov; 28(5):753-64. PubMed ID: 1778878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic analysis of amikacin twice and single daily dosage in immunocompromised pediatric patients.
    Krivoy N; Postovsky S; Elhasid R; Ben Arush MW
    Infection; 1998; 26(6):396-8. PubMed ID: 9861567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetic Model to Optimize Cefotaxime Dosing Regimen in Critically Ill Children.
    Béranger A; Oualha M; Urien S; Genuini M; Renolleau S; Aboura R; Hirt D; Heilbronner C; Toubiana J; Tréluyer JM; Benaboud S
    Clin Pharmacokinet; 2018 Jul; 57(7):867-875. PubMed ID: 28980166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic gram-negative infections.
    Giamarellou H; Yiallouros K; Petrikkos G; Moschovakis E; Vavouraki E; Voutsinas D; Sfikakis P
    J Antimicrob Chemother; 1991 May; 27 Suppl C():73-9. PubMed ID: 1906864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults.
    Tod M; Lortholary O; Seytre D; Semaoun R; Uzzan B; Guillevin L; Casassus P; Petitjean O
    Antimicrob Agents Chemother; 1998 Apr; 42(4):849-56. PubMed ID: 9559795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic variability of amikacin after once-daily and twice-daily dosing regimen in full-term neonates.
    Vučićević K; Rakonjac Z; Miljković B; Janković B; Prostran M
    J Pharmacol Sci; 2014; 124(2):138-43. PubMed ID: 24441865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic dosing of aminoglycosides: a controlled trial.
    Bartal C; Danon A; Schlaeffer F; Reisenberg K; Alkan M; Smoliakov R; Sidi A; Almog Y
    Am J Med; 2003 Feb; 114(3):194-8. PubMed ID: 12637133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections.
    Beaucaire G; Leroy O; Beuscart C; Karp P; Chidiac C; Caillaux M
    J Antimicrob Chemother; 1991 May; 27 Suppl C():91-103. PubMed ID: 1856149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amikacin once daily: a new dosing regimen based on drug pharmacokinetics.
    Maller R; Emanuelsson BM; Isaksson B; Nilsson L
    Scand J Infect Dis; 1990; 22(5):575-9. PubMed ID: 2259867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-a-day individualized amikacin dosing for suspected infection at birth based on population pharmacokinetic models.
    Labaune JM; Bleyzac N; Maire P; Jelliffe RW; Boutroy MJ; Aulagner G; Putet G
    Biol Neonate; 2001 Aug; 80(2):142-7. PubMed ID: 11509814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once- versus twice-daily amikacin regimen: efficacy and safety in systemic gram-negative infections. Scandinavian Amikacin Once Daily Study Group.
    Maller R; Ahrne H; Holmen C; Lausen I; Nilsson LE; Smedjegård J
    J Antimicrob Chemother; 1993 Jun; 31(6):939-48. PubMed ID: 8360131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of two amikacin dosing regimens in paediatric surgical patients.
    Forsyth NB; Botha JH; Hadley GP
    Ann Trop Paediatr; 1997 Sep; 17(3):253-61. PubMed ID: 9425382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of once-daily amikacin dose in critically ill adults.
    Šíma M; Hartinger J; Cikánková T; Slanař O
    J Chemother; 2018 Feb; 30(1):37-43. PubMed ID: 28950787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amikacin dosing and monitoring in spinal cord injury patients: variation in clinical practice between spinal injury units and differences in experts' recommendations.
    Vaidyanathan S; Peloquin C; Wyndaele JJ; Buczynski AZ; Almog Y; Markantonis SL; Jayawardena V; Soni BM; Cannon J; Vidal J
    ScientificWorldJournal; 2006 Feb; 6():187-99. PubMed ID: 16493523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model.
    Robaux MA; Dube L; Caillon J; Bugnon D; Kergueris MF; Navas D; Le Conte P; Baron D; Potel G
    J Antimicrob Chemother; 2001 May; 47(5):617-22. PubMed ID: 11328773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and pharmacokinetic study of a single daily dose of amikacin in paediatric patients with severe gram-negative infections.
    Kafetzis DA; Sianidou L; Vlachos E; Davros J; Baïramis T; Papandreou Y; Paraskaki E; Scouroliakou M; Hadzis A; Papadatos J
    J Antimicrob Chemother; 1991 May; 27 Suppl C():105-12. PubMed ID: 1906861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.